Evaluation of the MP Diagnostics HTLV Blot 2.4

HTLV-I Infections Clinical Trial

Official title:

Evaluation of the MP Diagnostics HTLV Blot 2.4

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT01467024
• Other study ID #: MP-EIA-HTLV-001B
• Status: Unknown status
• Phase: N/A
• First received: October 31, 2011
• Last updated: November 7, 2011
• Start date: November 2011
• Est. completion date: June 2012

Study information

• Verified date: November 2011
• Source: MP Biomedicals, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is:

1. To assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4.

2. To conduct a sensitivity analysis of the HTLV Blot 2.4 using a known positive population.

Description:

This is a retrospective study designed to assess the validity and reproducibility of the MP Diagnostics IVD device, the HTLV Blot 2.4 (MP Blot), in various populations. The study will be conducted at three geographical distinct locations.

The validity of the MP Blot will be assessed by calculating the following:

1. Percent negative agreement with CDPHL Algorithm on 200 EIA negative specimens

2. Percent positive agreement with CDPHL Algorithm on 200 EIA repeat reactive specimens

The sensitivity of the MP Blot will be evaluated by testing 200 known positive specimens. The study will be performed using three product lots at three clinical sites.

The reproducibility of the MP Blot will be assessed by testing two replicates of a three member panel at three clinical testing sites with each of three lots of product over multiple days by three operators.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 600
• Est. completion date: June 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• EIA Negative Population

1. Male or female

2. Completion of a health history evaluation for routine donor screening

3. Willing and able to provide informed consent

4. Negative screening assay results for all ARC screening assays

• EIA Repeat Reactive Population

1. Male or female

2. Completion of a health history evaluation for routine donor screening

3. Willing and able to provide informed consent

4. Previous RR result by bioMerieux ELISA, Abbott EIA, and / or Abbott ChLIA PRISM

• Known Positive Population

1. Male or female

2. Willing and able to provide informed consent

3. Previous reactive screening test using either the bioMerieux ELISA, the Abbott EIA or the Abbott ChLIA PRISM, followed by supplemental testing

Exclusion Criteria:

• EIA Negative Population

1. Inadequate sample volume for testing

2. Unable to provide samples that meet the sample suitability requirements for testing

3. Positive screening result for any infectious disease tested by ARC

• EIA Repeat Reactive Population

1. Inadequate sample volume for testing

2. Unable to provide samples that meet the sample suitability requirements for testing

3. Positive result for HIV, HBV, HCV, or any other infectious disease

• Known Positive Population

1. Unwilling or unable to provide informed consent

2. Unable to provide adequate sample volume for testing

3. Unable to provide samples that meet the sample suitability requirements for testing

4. Positive result for HIV

Related Conditions & MeSH terms

• Communicable Diseases
• HTLV I Associated Myelopathies
• HTLV I Associated T Cell Leukemia Lymphoma
• HTLV-I Infections
• HTLV-II Infections
• Human T-lymphotropic Virus 1
• Human T-lymphotropic Virus 2
• Infection
• Leukemia, T-Cell
• Leukemia-Lymphoma, Adult T-Cell
• Spinal Cord Diseases

Intervention

Other:
• CDPHL Algorithm
Supplemental testing algorithm performed by the CDPHL.

Locations

Country	Name	City	State
United States	California Department of Public Health	Richmond	California
United States	LABS, Inc	St. Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
MP Biomedicals, LLC	Vital Systems Inc.

Country where clinical trial is conducted

United States,